Abstract
Epicillin was administered orally, using a twice daily dosage regimen, to a total of 266 patients suffering from mild to moderate respiratory or urinary tract infections. The dosage used was 500 mg twice daily in respiratory tract infections and 1000 mg twice daily in urinary tract infections.
The incidence of adverse reactions was 10% in this study and with one exception all were mild to moderate in severity.
Epicillin administered on a twice daily basis proved to be efficacious against the common sensitive pathogens responsible for infection of the respiratory and urinary tracts. An excellent response was reported in 49% of the patients, a good response obtained in 46% and a fair response was achieved in 4%.
The advantages of a twice daily dosage regimen are pointed out.
Get full access to this article
View all access options for this article.